Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Exclusion Criteria

• •Less than or equal to 3 weeks since receiving treatment with biologic, small molecule, chemotherapy or other agent for non-small cell lung cancer and 28 days since any prior immunotherapy (such as nivolumab)
• •History of a concurrent or second malignancy, except for specified exceptions in the protocol or any other cancer that has been in complete remission for ≥ 5 years
• •Known positive status for human immunodeficiency virus (HIV)
• •Chronic active or acute viral hepatitis A, B, or C infection or hepatitis B or C carrier
• •Presence of ≥ Grade 2 peripheral neuropathy
• •A history of uveitis and/or scleritis
• •Retinal pathology beyond normal age-related processes
• •Evidence of a retinal vein occlusion on ophthalmological exam or a history of retinal vein occlusion
• •History of newly diagnosed or uncontrolled glaucoma/intraocular pressure \> 21 mm Hg as measured by tonography
• •Use of daily and/or chronic oral or ocular steroids. Individuals must be off daily steroids for at least 3 weeks prior to enrolling into the trial
• •History of interstitial pneumonitis
• •History of long QT syndrome or whose corrected QT interval (QTc) measured (Fridericia method) at screening is prolonged (\> 480 ms for males and females)